Additionally, the evidence that CLL cells overexpress HLA-E, the main ligand for CD94/NKG2A, has provided the rationale for using the humanized IgG4 anti-CD94/NKG2A mAb monalizumab (IPH2201) for CLL treatment [138] (Figure 3B). The gene discussed is HLA-E; the disease is B-cell chronic lymphocytic leukemia.